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Illicit Methylphenidate Use in an Undergraduate Student
Sample:  Prevalence and Risk Factors
Christian J. Teter, Pharm.D., Sean Esteban McCabe, Ph.D., Carol J. Boyd, Ph.D., and 
Sally K. Guthrie, Pharm.D.
Study Objectives. To assess the prevalence of illicit methylphenidate use
among undergraduate college students at a large university, and to identify
alcohol and other drug use behaviors, as well as the negative consequences
and risk factors, associated with illicit methylphenidate use.
Design. Internet survey.
Setting. Large public university.
Subjects. Thirty-five hundred randomly selected undergraduate students.
Measurements and Main Results. Of the 2250 students who completed the
survey, 3% reported past-year illicit methylphenidate use.  Illicit
methylphenidate users were significantly more likely to use alcohol and
drugs and report adverse alcohol- and drug-related consequences than
prescription stimulant users or students who did not use stimulants.
Undergraduate men and women were equally likely to report past-year
illicit methylphenidate use.  Weekly party behavior was significantly
associated with past-year illicit methylphenidate use.
Conclusion. Illicit use of prescription-only stimulants on college campuses is
a potentially serious public health issue.  More work is needed to promote
understanding and awareness of this problem among clinicians and
researchers.
(Pharmacotherapy 2003;23(5):609–617)
The misuse of alcohol and illicit drugs among
traditional-age undergraduate students remains a
major public health problem for American
colleges and universities.1–4 College students
who misuse alcohol and other drugs experience
significantly higher rates of negative conse-
quences than students who do not use these
substances.5–8
Recent years have brought increasing evidence
that college students are abusing not only alcohol
but also prescription drugs.2 Indeed, this abuse
appears to coincide with the increasing number
of prescriptions that have been written for
psychostimulants.9 Methylphenidate (Ritalin;
Novartis Pharmaceuticals Corp, East Hanover,
NJ) and other psychostimulants, such as D-
amphetamine, are the preferred pharmacotherapy
for treating attention-deficit–hyperactivity
disorder (ADHD).  Although methylphenidate is
highly effective for the treatment of ADHD,10 it
has potential for abuse and diversion.11 The licit
and illicit use of methylphenidate has increased
dramatically over the past 10 years,9, 12 but
research on patterns and consequences of its use
has been limited in the college population.  We
sought to assess the prevalence of illicit
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methylphenidate use among undergraduate
students at a large public university.  Other goals
of this study were to identify alcohol and drug
use behaviors, as well as the negative conse-
quences and risk factors, associated with illicit
methylphenidate use.
Methods
The University of Michigan’s institutional
review board approved the protocol for this
study, and all respondents gave informed
consent.  The study was conducted during a 1-
month period between March and April of 2001,
drawing on a total undergraduate population of
21,055 full-time students (10,732 women and
10,323 men).  A random sample of 3500 full-
time University of Michigan undergraduate
students was drawn from the Registrar’s Office.
The students were sent a letter through e-mail
describing the study and inviting recipients to
self-administer the Student Life Survey.  Students
were told to access the Web survey by clicking on
an e-mail link.
Survey
The Student Life Survey was developed and
pilot tested in 1993.  It draws from items in the
Monitoring the Future (MTF) study,13 the Core
Alcohol and Drug Survey,5 and the College
Alcohol Study.14 Design, procedures, and
reliability measures pertaining to the Student Life
Survey are described in more detail elsewhere.15, 16
The survey was designed to collect demographic
information, including sex, age, primary ethnic
origin, primary religious affiliation, grade point
average, fraternity or sorority affiliation, average
annual family income, and living arrangements.
It also queried students about alcohol and drug
use, prescription drug use, sexual behavior, and
adverse alcohol- and drug-related consequences.
Illicit drug use was assessed by the following
question:  “Have you ever used the following
types of drugs…(a) in your lifetime, (b) during
the past 12 months, or (c) during the past 30
days?  Do not include drugs used under a
doctor’s prescription.  (Check all that apply).”
The following substances were listed as possible
answers:  “marijuana, cocaine in any form, LSD,
other psychedelics, amphetamines or meth-
amphetamine, crystal meth, Ritalin, downers,
tranquilizers, heroin, other narcotics, inhalants,
Ecstasy (MDMA), GHB, Rohypnol, anabolic
steroids, and other (please specify).”  For those
drug categories that included a broad range of
substances, examples were given for clarification.
For example, for “other narcotics,” examples
given were Vicodin, codeine, Demerol, Percodan,
methadone, opium, and morphine.  Respondents
were given two response categories (yes and no).
Endorsement of “yes” was defined as illicit drug
use.  We created two illicit drug indexes for each
student by summing the number of responses
indicating that the student had used an illicit
substance in the past year or past month,
respectively.  If respondents indicated they had
used a drug in their lifetime, they received a
follow-up question asking when they began using
the specific drug.  The four response categories
were elementary school, junior high school, high
school, and college.  Another index for each
student was created to assess the start of drug use
before entering college.  This index reflected the
summation of the number of illicit drugs a
student had used in high school or earlier.
To assess prescription drug use, the survey
asked the following question:  “Based on a
doctor’s prescription, have you ever used the
following types of drugs…(a) in your lifetime? or
(b) in the past 12 months?”  Five categories of
prescription drugs were identified:  stimulants
(e.g., weight loss pills, Ritalin), sleeping aids
(e.g., Halcion), minor tranquilizers (e.g., Valium,
Ativan), prescription analgesics (e.g., codeine,
Darvon, Tylenol No. 3), and antidepressants (e.g.,
Prozac, Paxil, Zoloft, Luvox).  Respondents were
given two response categories (yes and no).  An
endorsement of “yes” was defined as prescription
drug use.
Primary and secondary alcohol-related
consequences were assessed by items adapted
from national studies of alcohol and drug use
among college students.5, 14 For example,
primary consequences associated with drinking
included missing a class, developing a hangover,
damaging property, being hurt or injured, and
having unplanned sex.  The response scale for
each item ranged from 1 (never) to 4 (6 or more
times).  A primary alcohol-related consequences
index was created by summing each respondent’s
scores for the 23 survey items addressing primary
alcohol-related consequences in the past year.
Secondary consequences were assessed using 10
questions that explored consequences associated
with others’ use of alcohol in the past year.
Examples were disrupted sleep, experienced an
unwanted sexual advance by someone drunk or
high, and had to take care of someone with a
drinking or drug problem.  The response scale for
each item ranged from 1 (never) to 5 (10 or more
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times).  A secondary alcohol-related consequences
index was created by summing each respondent’s
scores for the 10 items in this category.
For the survey to qualify as being completed,
the student must have answered at least two
thirds of the questions, including those
addressing demographic characteristics, alcohol
use, illicit drug use, prescription drug use both as
prescribed by a doctor and not as prescribed, and
adverse alcohol- and drug-related consequences.
After completing the survey, the student would
receive a $10 gift certificate to a local bookstore.
Statistical Analysis
We used x2 tests to compare student
demographics, prescription drug use, and alcohol
and drug use across three distinct groups, with
“the past 12 months” as the time frame.  The
three groups were as follows:  undergraduate
students who reported taking methylphenidate
not as prescribed by a doctor (illicit use),
undergraduate students who reported taking
stimulant drugs as prescribed by a doctor, and
undergraduate students who reported no
stimulant use.  In addition to x2 tests, 1-way
analyses of variance were used to compare illicit
methylphenidate users, prescription stimulant
users, and nonstimulant users across several
continuous measures.  Post hoc pairwise
comparisons were conducted using Tukey’s
honestly significant difference test.  We set the a
a priori at 0.05.  Finally, multivariate logistic
regression was used to assess factors that might
be associated with illicit methylphenidate use,
using two separate models for lifetime and past-
year use.  All analyses were conducted with SPSS
software (SPSS Inc., Chicago, IL).
Results
The response rate was 64% (70% for women,
58% for men), which was better than average
when compared with national college-based
studies of alcohol and other drugs.4 The total
sample consisted of 2250 undergraduate students
with a mean ± SD age of 20.07 ± 1.70 years.
Table 1 shows respondents’ demographics and
alcohol or drug use behaviors.  Prevalence rates
for various illicit substances in the past year
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Table 1.  Demographics and Alcohol or Drug Use Behaviors of Illicit Methylphenidate Users, Prescription Stimulant Users,
and Nonstimulant Users
Past-Year
Past-Year Illicit Prescription Past-Year
Methylphenidate Stimulant Nonstimulant Statistically Significant
Users (%) Users (%) Users (%) Differences Between
Variable (n=57) (n=25) (n=2168) the Three Groupsa
Sex NS
Women 59.6 56.0 56.2
Men 40.4 44.0 43.8
Class year b
Freshman 35.7 12.5 23.5
Sophomore 5.4 20.8 25.5
Junior 23.2 45.8 28.2
Senior 35.7 20.8 22.8
Race NS
African-American 1.8 0 4.5
Asian 1.8 0 15.2
White 84.2 88.0 70.4
Other 12.3 12.0 9.8
Got drunk in high school or before 98.2 54.2 58.3 b, c
Binge drinking in the past 2 weeks 98.2 69.6 48.3 b, c, d
Marijuana use in high school or before 91.2 50.0 28.1 b, c
Marijuana use in the past year 100.0 50.0 29.9 b, c
Ecstasy (MDMA) use in the past year 57.9 12.5 5.3 b, c
Any cigarette use in the past month 77.2 32.0 22.0 b, c
MDMA = 3,4-methylenedioxymethamphetamine.
ap<0.01, based on x2.
bIllicit methylphenidate users differed from nonstimulant users.
cIllicit methylphenidate users differed from prescribed stimulant users.
dPrescribed stimulant users differed from nonstimulant users.
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within our sample were consistent with the
findings of a comparable national sample from
the Monitoring the Future study.2 Of the 57
students who reported illicit methylphenidate use
in the past year, 2% began taking methyl-
phenidate in junior high, whereas 19% started in
high school, and 79% began in college.  None of
the students who reported lifetime or past-year
illicit methylphenidate use injected the drug, and
no information was available on intranasal
administration.
Illicit methylphenidate users were significantly
more likely to have used various other substances
in the past year and the past month than either
prescription stimulant users or nonstimulant
users.  In particular, 100% and 58% of the past-
year illicit methylphenidate users had used
marijuana and Ecstasy (MDMA [3,4-methylene-
dioxymethamphetamine]), respectively, in the
past year.  Moreover, 98% of illicit methyl-
phenidate users reported a binge drinking
episode in the past 2 weeks.
Illicit methylphenidate users reported
consuming significantly more mean
drinks/occasion in the past month than either
prescription stimulant users or nonstimulant
users.  Furthermore, illicit methylphenidate users
reported having taken 3 times the number of
illicit drugs, other than methylphenidate, in the
past year as were used by prescription stimulant
users, and 8 times the number of illicit drugs
used by nonstimulant users in the past year
(Table 2).  Illicit methylphenidate users also
reported significantly higher mean levels of
negative primary and secondary alcohol- or drug-
related consequences in the past year than
prescription stimulant users or nonstimulant
users.  In fact, while illicit methylphenidate users
reported significantly higher rates of every
individual primary and secondary consequence
relative to prescription stimulant users and
nonstimulant users, there were no statistically
significant differences between prescription
stimulant users and nonstimulant users, with the
exception of one primary consequence:  prescription
stimulant users were more likely to report
missing a class due to drinking (44%) than
nonstimulant users (25%).
Our x2 analysis revealed that weekly party
behavior, having multiple sexual partners,
fraternity or sorority affiliation, and family
income were all significantly associated with both
lifetime and past-year illicit methylphenidate use
(p<0.001 for all associations, results not shown).
Most notably, the prevalence of illicit methyl-
phenidate use in the past year was 14% among
students who reported 10 or more hours of
weekly party behavior.
Multivariate Results
As shown in Table 3, multivariate logistic
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Table 2.  Alcohol or Drug Use Behaviors and Related Negative Consequences Associated with Illicit Methylphenidate Use
Past-Year Statistically
Past-Year Illicit Prescription Past-Year Significant
Methylphenidate Stimulant Nonstimulant Differences
Users Users Users Between the
(n=57) (n=25) (n=2168) Three Groupsa
No. of illicit drugs used in the past year, 3.84 ± 0.14 1.25 ± 0.21 0.49 ± 0.02 b, c, d
excluding illicit methylphenidate (0–16)
No. of illicit drugs used in the past month, 1.95 ± 0.08 0.67 ± 0.13 0.22 ± 0.01 b, c, d
excluding illicit methylphenidate (0–16)
No. of pre-college illicit drugs used, 2.30 ± 0.13 1.10 ± 0.20 0.44 ± 0.02 b, c, d
excluding illicit methylphenidate (0–16)
No. of drinks/occasion in the past 30 days (0–12) 7.02 ± 0.37 4.70 ± 0.58 4.10 ± 0.06 b, c
Primary alcohol- or drug-related 9.68 ± 0.52 4.39 ± 0.81 3.90 ± 0.09 b, c
consequences index (0–23)
Secondary alcohol- or drug-related 5.28 ± 0.31 3.60 ± 0.46 3.20 ± 0.05 b, c
consequences index (0–10)
Grade point average (0–4.0) 3.13 ± 0.06 3.33 ± 0.09 3.28 ± 0.01 b
Data are mean ± SE.
a1-way analysis of variance followed by post hoc Tukey’s honestly significant difference test, p<0.05.
bIllicit methylphenidate users differed from nonstimulant users.
cIllicit methylphenidate users differed from prescription stimulant users.
dPrescription stimulant users differed from nonstimulant users.
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regression revealed that after controlling for the
identified student characteristics, students who
reported lifetime or past-year illicit methyl-
phenidate use were significantly more likely than
other students to engage in party behavior of
more than 5 hours/week.  In addition, after we
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Table 3.  Multivariate Logistic Regression Results Examining Correlates of Illicit Methylphenidate Use During Lifetime and
Past Year (two separate models)
Lifetime Past-Year
Illicit Methylphenidate Use Illicit Methylphenidate Use
Characteristic Adjusted ORa 95% CI Adjusted ORa 95% CI
Sex
Men 1.00 1.00
Women 0.74 0.48–1.15 1.00 0.55–1.85
Race
White 1.00 1.00
Nonwhite 0.59 0.32–1.07 0.76 0.34–1.71
Fraternity or sorority affiliation
Fraternity or sorority member 1.00 1.00
Nonmember 0.66 0.37–1.15 0.70 0.35–1.42
Religious affiliation
Jewish 1.00 1.00
Catholic 0.83 0.41–1.68 0.55 0.24–1.28
None 1.38 0.66–2.88 0.76 0.30–1.94
Other 1.06 0.52–2.15 0.37b 0.15–0.95
Family income ($)
< 50,000 1.00 1.00
50,000–99,999 0.95 0.39–2.33 0.99 0.22–4.43
100,000–249,999 1.42 0.62–3.22 2.13 0.55–8.15
‡ 250,000 2.89b 1.19–7.04 2.81 0.69–11.49
Don’t know 0.68 0.25–1.84 1.27 0.29–5.53
Weekly party behavior (hrs)
None 1.00 1.00
1–4 1.01 0.47–2.17 1.91 0.40–9.04
5–9 2.32b 1.06–5.08 5.10b 1.10–23.53
‡ 10 4.35c 1.78–10.64 12.62c 2.56–62.19
Grade point average
< 2.5 1.00 1.00
2.5–2.9 0.55 0.19–1.61 0.34 0.09–1.27
3.0–3.4 0.71 0.27–1.85 0.43 0.14–1.32
‡ 3.5 0.54 0.20–1.46 0.20c 0.06–0.68
Class year
Freshmen 1.00 1.00
Sophomore 0.49 0.20–1.18 0.10b 0.02–0.59
Junior 0.53 0.20–1.42 0.32 0.06–1.87
Senior 0.98 0.36–2.63 0.52 0.09–3.02
Living arrangement
Residence hall 1.00 1.00
Fraternity or sorority 0.44 0.12–1.58 0.56 0.06–5.01
House or apartment 1.16 0.49–2.74 1.66 0.31–8.84
Other 2.16 0.63–7.42 1.72 0.13–22.50
No. of sexual partners in the past year
None 1.00 1.00
1 2.31c 1.25–4.25 1.42b 0.59–3.41
2 3.78d 1.86–7.68 3.23d 1.29–8.13
3 7.00d 3.17–15.44 5.67c 2.02–15.89
4 3.85b 1.25–11.92 7.30d 2.09–25.53
‡ 5 6.19d 2.32–16.51 7.35d 2.26–23.85
OR = odds ratio; CI = confidence interval.
aOdds ratios are adjusted for all other correlates.
bp<0.05.
cp<0.01.
dp<0.001.
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controlled for the other variables, the data
showed no significant associations between sex,
race, social fraternity or sorority affiliation, or
living arrangement with past-year or lifetime
illicit methylphenidate use.
Discussion
Approximately 3% (57 students) of our sample
of 2250 undergraduate college students had used
methylphenidate in the past year without a
doctor’s prescription.  This is consistent with the
limited prevalence data published in the
literature regarding illicit use of methylphenidate
among adolescents.  For instance, the Monitoring
the Future study, which tracked illicit methyl-
phenidate use in nationally representative
samples of 12th grade students, found that illicit
use has increased dramatically over the past 5
years, with a current annual prevalence of
approximately 3%.12 Similarly, an Indiana survey
revealed that approximately 4% of 12th grade
students in that state had used nonprescribed
methylphenidate in the past year.17 The
Monitoring the Future and Indiana sample
populations both consisted of 12th grade
students, not college populations; in fact, limited
data have been published on illicit methyl-
phenidate use among college students.  One
single-institution study found that more than
16% of the students surveyed (283 students) at a
4-year public liberal arts college had tried
methylphenidate for nonmedical purposes.18
Because there are significant differences in drug-
using behaviors among different colleges and
universities,4 the extent of illicit methylphenidate
use among college students nationwide remains
unknown, although it appears to be a growing
problem on some campuses.
Further evidence illustrating this potentially
serious public health issue comes from a variety
of anecdotal case reports of methylphenidate
abuse in the literature,19–24 as well as empirical
evidence that methylphenidate has abuse
potential.25 According to an extensive literature
review, in 48 of 60 studies (80%) assessing the
reinforcing, discriminative-stimulus, or
subjective effects of methylphenidate in
nonhuman and human subjects, methyl-
phenidate appeared to have an abuse potential
similar to that of D-amphetamine and cocaine.25
Furthermore, methylphenidate and cocaine show
similar pharmacokinetic and pharmacodynamic
profiles in the human brain26 and have very
similar actions at the dopamine transporter.27
Thus, it is possible that methylphenidate has an
abuse potential similar to cocaine or D-amphetamine.
However, according to the National Institute on
Drug Abuse Community Epidemiology Work
Group, actual abuse rates for methylphenidate
appear to be much less than those for cocaine
and D-amphetamine in the United States.28
In our sample, rates of cigarette smoking,
alcohol use, and illicit drug use were significantly
higher among undergraduate college students
who used illicit methylphenidate than among
those who used prescribed stimulants or who did
not report any stimulant use.  Not only were
illicit methylphenidate users more likely to be
polydrug users, they were also more likely to
have begun drug use in high school or earlier, as
compared with the other two groups.  For
instance, 91% of past-year illicit methylphenidate
users had used marijuana in high school or
before.
Notably, the drug-use behaviors of students
using prescribed stimulants more closely
resembled the drug-use behaviors of the
nonstimulant users than they did the illicit
methylphenidate users.  This finding accords
with the conclusions of a research group who
determined that effective treatment of ADHD
with psychostimulants, such as methylphenidate,
may decrease young patients’ risk of developing a
substance use disorder.29 These researchers, after
controlling for subjects’ age, socioeconomic
status, lifetime risk of conduct disorder at
baseline, and lifetime history of substance abuse
disorders in the subjects’ parents, found that
pharmacotherapy was associated with an 85%
reduction in the risk for substance abuse
disorders in youths with ADHD.29 Although
there is disagreement about the exact relationship
between ADHD, psychostimulant use, and the
risk for developing a substance use disorder, our
sample of students using prescribed stimulants
exhibited rates of substance use that were similar
to those of nonstimulant users.  These students
may have experienced a protective effect from
substance use by effective treatment with
methylphenidate, although larger samples and
additional information regarding ADHD
diagnosis would be needed to establish this
association clearly.
It is well known that alcohol or drug use
behaviors cluster together with other problem
behaviors.30 Our findings suggest that the factors
associated with illicit methylphenidate use are
very similar to those previously found to be
associated with use of other illicit drugs among
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college students.1, 31 Having a greater number of
sex partners and engaging in frequent partying in
college have been shown to be significantly
associated with higher rates of marijuana31 and
Ecstasy3 use.  However, although these behaviors
are associated with illicit drug use, the causal role
of illicit methylphenidate use in our students
who reported other risky behaviors or negative
alcohol- or drug-related consequences cannot be
clearly established.
According to the Drug Enforcement Adminis-
tration, the overall production (aggregate
production quota) of methylphenidate has
increased dramatically since 1990.32 This
increase in availability may partly reflect an
increase in diversion, but it also may be
indicative of a dramatic increase in recognition
and diagnosis of ADHD, combined with
realization that ADHD symptoms often continue
into adulthood.33 Although we did not set out to
examine the diversion of prescribed methyl-
phenidate, we found an apparent relationship
between illicit methylphenidate use and
prescription stimulant use in university residence
halls.  For instance, in six residence halls where
there was no reported prescription stimulant use,
there was also no reported illicit methylphenidate
use.  However, in three of four residence halls
where prescription stimulant use was present,
illicit methylphenidate use was reported.  Limited
sample sizes prevented us from detecting
statistically significant differences in illicit
methylphenidate use among particular residence
halls.  More research is needed in this area
because diversion of prescribed stimulants has
been documented among children and adoles-
cents in both Canada and the United States.34, 35
Limitations
Several limitations need to be considered when
weighing the potential implications of this study.
The survey question regarding prescribed
stimulants included “weight loss pills” as an
example in addition to “Ritalin,” which limited
our findings.  Since we cannot assume that 100%
of respondents answering yes to the prescription
stimulant response had taken methylphenidate
for ADHD, based on information provided by the
Drug Enforcement Administration and the
Council on Scientific Affairs of the American
Medical Association, approximately 80% of
prescribed methylphenidate is used for children
diagnosed with ADHD,32 and more than 90% of
stimulant use for the treatment of ADHD in the
United States is methylphenidate.11
The survey question assessing illicit methyl-
phenidate use did not carry the same limitation
because it listed only Ritalin as a response.  We
did not determine the quantity of illicit methyl-
phenidate that students used on each occasion,
the reasons for use, or whether any respondents
had taken methylphenidate intranasally.
The power of our statistical analyses, in
particular the multivariate logistic regression,
was limited by the number of students who
reported prescribed stimulant use (25 students)
and illicit methylphenidate use (57 students).
Our findings regarding possible diversion were
limited because our analysis was based on a
probability sample of undergraduate students
living in residence halls.  Therefore, we could not
accurately assess actual diversion rates based on
the entire residence hall population.  Also, we did
not ask how illicit methylphenidate users were
obtaining their methylphenidate.  Finally, our
study population consisted of a predominantly
white and affluent group of undergraduate
college students.  More research is needed to
compare our findings with those resulting from
more diverse samples, including young adults
not attending college.
Implications for Future Practice
Physicians and pharmacists must balance the
risks and benefits of psychostimulant
pharmacotherapy carefully when diagnosing,
treating, and monitoring their patients.  “Health
care providers must cooperate in detecting abuse
and minimizing diversion.”33 School social
workers, nurses, and administrators should
consider several prevention strategies when
dealing with abusable prescription drugs; clearly,
enhanced screening and assessment can lead to
early identification of potential methylphenidate
abusers.
Clinicians should be familiar with nonpsycho-
stimulant alternatives for the treatment of ADHD
and other disorders.  For example, the Food and
Drug Administration recently approved
atomoxetine, a nonstimulant norepinephrine
reuptake inhibitor that has been shown to be safe
and effective for treatment of ADHD in children,
adolescents, and adults.36 Alternatively, the use
of pharmaceutical delivery systems that are not
easily manipulated for injection or inhalation
might help limit the abuse of methylphenidate
and other prescription psychostimulants.  For
example, at least one published report describes
615
PHARMACOTHERAPY  Volume 23, Number 5, 2003
failed attempts at abusing Concerta (methyl-
phenidate; McNeil Consumer & Specialty
Pharmaceuticals, Fort Washington, PA) by the
intranasal route.37 Concerta uses an osmotic
pressure delivery system to deliver methyl-
phenidate at a controlled rate.  This system may
be difficult to use by alternate routes of
administration, due to its physical make-up and
insoluble components.  Finally, inappropriate use
of prescription psychostimulants may be
hindered by the use of centralized prescription
databases, such as the newly introduced
Michigan Automated Prescription System.38 This
system, which allows clinicians to access patients’
prescription records, allows for more thorough
monitoring and detection of drug-seeking
behaviors, such as doctor shopping or the use of
multiple pharmacies to obtain controlled
substances.
Implications for Future Research
Future research is needed to further clarify the
relationships between ADHD, treatment with
psychostimulants, and the risk for substance use
in different populations (e.g., age, gender, race,
socioeconomic status).  Another important
question is whether exposure to abusable
psychoactive prescription drugs, such as psycho-
stimulants, leads to a higher prevalence of other
illicit substance use.  Qualitative research should
be used to examine the reasons for illicit
methylphenidate use across different populations.
Examples of reasons that should be explored are
weight loss, euphoria, prolonging study time, and
prolonging the effects of intoxicating agents such
as alcohol.  Furthermore, studies assessing the
route of administration, particularly the
intranasal route, should be conducted, as should
be studies to determine whether certain dosage
forms (e.g., long-acting preparations and osmotic
delivery systems) have less abuse potential than
other dosage forms.  Longitudinal studies could
determine patterns of illicit methylphenidate use
in different populations.  Such studies might help
clarify the differences in patterns of abuse
between methylphenidate and other illicit
psychostimulants, such as cocaine and amphet-
amines.  Longitudinal studies are also needed to
examine how various patterns of illicit methyl-
phenidate use during adolescence are related to
long-term morbidity and mortality.
Conclusion
Of the 2250 students who completed our
survey, 3% reported past-year illicit methyl-
phenidate use.  These students were significantly
more likely to use alcohol and drugs and report
adverse alcohol- and drug-related consequences
than prescription stimulant users or students
who did not use stimulants.  However, more
work is needed to explore the problem of illicit
use of prescription-only stimulants on college
campuses.  Such efforts can provide clinicians
and researchers with a clear understanding and
awareness of this potentially serious public
health issue.
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